Organogenesis Holdings Inc.

Total Valuation

Organogenesis Holdings Inc. carries a market capitalization of 291.45M, placing it among publicly traded companies globally. Its enterprise value stands at 417.53M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Organogenesis Holdings Inc. currently has 128.67M shares outstanding.

Valuation Ratios

Organogenesis Holdings Inc. trades at a trailing price-to-earnings ratio of 25.06. The price-to-sales ratio is 0.59, and the price-to-book ratio stands at -5.36.

Enterprise Valuation

On an enterprise value basis, Organogenesis Holdings Inc. trades at an EV/EBITDA multiple of 10.39 and an EV/FCF ratio of 9.40. The EV/Sales ratio of 0.81 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 58.34 provides insight into valuation relative to core operating earnings.

Financial Position

Organogenesis Holdings Inc. maintains a current ratio of 3.53, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Over the trailing twelve months, Organogenesis Holdings Inc. has paid 1.56M in income taxes, reflecting an effective tax rate of 36.47.

Stock Price Statistics

Organogenesis Holdings Inc.'s stock has declined approximately -19.39502% over the past 52 weeks. The 50-day moving average sits at 2.45, while the 200-day moving average is 3.90.

Income Statement

Over the trailing twelve months, Organogenesis Holdings Inc. generated 512.59M in revenue and converted that into 2.72M in net income, yielding earnings per share of 0.02. EBITDA reached 40.18M, while operating income came in at 7.16M.

Balance Sheet

Organogenesis Holdings Inc. holds 91.38M in cash and equivalents against 70.86M in total debt, resulting in a net debt position of -91.38M. Total book value stands at -56.22M, with working capital of 192.48M providing operational flexibility.

Cash Flow

Organogenesis Holdings Inc. produced 30.75M in operating cash flow over the past twelve months. After subtracting -13.67M in capital expenditures, free cash flow totaled 17.08M - equivalent to 0.13 per share.

Margins

Organogenesis Holdings Inc. operates with a gross margin of 72.77, reflecting its pricing power and cost economics. The operating margin of 1.40 and net profit margin of 0.53 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of 132.65 indicates the proportion of earnings distributed to shareholders.

Scores

Organogenesis Holdings Inc. posts an Altman Z-Score of 2.72, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.